Amber Larimore-Olguin
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 32.8% of the total. Reporting peaked in 2021 at $1,920 and has fallen 98.4% since, to $31 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$492
- Boehringer Ingelheim$365
- GSK$244
- Pfizer$219
- AstraZeneca$214
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $1,281 |
| Novo Nordisk | 27 | $492 |
| Boehringer Ingelheim | 28 | $365 |
| GSK | 19 | $244 |
| Pfizer | 15 | $219 |
| AstraZeneca | 14 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $114 |
| Astellas Pharma US Inc | 5 | $88 |
| Jazz Pharmaceuticals Inc. | 6 | $83 |
| Amgen | 5 | $80 |
| Amarin Pharma, Inc. | 6 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| Merck | 4 | $66 |
| Lilly USA, LLC | 4 | $58 |
| Corium, LLC | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Halozyme Inc | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Genentech USA, Inc. | 4 | $38 |
| Bayer | 2 | $35 |
| Harmony Biosciences LLC | 2 | $30 |
| Edwards Lifesciences | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Si-bone, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,903 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 48 | $467 |
Paid to pharmacies, not to this prescriber.
Other family in Azle
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.